Indaptus Therapeutics (INDP) S-4/A 12 May 21 Registration of securities issued in business combination transactions (amended) Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2020
Document Type	S-4/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Entity Registrant Name	Intec Parent Inc.
Entity Central Index Key	0001857044
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	12 Hartom Street
Entity Address, Address Line Two	Har Hotzvim
Entity Address, City or Town	Jerusalem
Entity Address, Postal Zip Code	9777512
City Area Code	+972-2
Local Phone Number	586-4657
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
MWE Corporate Services, LLC [Member]
Entity Address, Address Line One	1007 N. Orange Street,
Entity Address, Address Line Two	10th Floor
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19801
City Area Code	(302)
Local Phone Number	485-3907

Consolidated Balance Sheets

Consolidated Balance Sheets - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 14,671	$ 9,292
Investment in marketable securities (Note 3)		770
Prepaid expenses and other receivables (Note 8a)	297	3,683
TOTAL CURRENT ASSETS	14,968	13,745
NON-CURRENT ASSETS:
Property and equipment, net (Note 4)	1,394	2,575
Operating lease right-of-use assets (Note 6d)	817	1,243
Other assets (Note 6e(1))	3,717	3,717
TOTAL NON-CURRENT ASSETS	5,928	7,535
TOTAL ASSETS	20,896	21,280
Accounts payable and accruals:
Trade	368	3,507
Other (Note 8b)	4,966	4,835
TOTAL CURRENT LIABILITIES	5,334	8,342
LONG-TERM LIABILITIES:
Operating lease liabilities (Note 6d)	338	799
Other liabilities (Note 9)	691	604
TOTAL LONG-TERM LIABILITIES	1,029	1,403
TOTAL LIABILITIES	6,363	9,745
SHAREHOLDERS’ EQUITY:
Ordinary shares, with no par value - authorized: 17,500,000 and 5,000,000 Ordinary Shares as of December 31, 2020 and December 31, 2019, respectively; issued and outstanding: 4,321,296 and 1,811,431 Ordinary Shares as of December 31, 2020 and December 31, 2019, respectively	727	727
Additional paid-in capital	217,357	200,231
Accumulated deficit	(203,551)	(189,423)
TOTAL SHAREHOLDERS’ EQUITY	14,533	11,535
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 20,896	$ 21,280

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - Intec Pharma Ltd. [Member] - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Ordinary shares, par value (in Dollars per share)	$ 0	$ 0
Ordinary shares, authorized	17,500,000	5,000,000
Ordinary shares, issued	4,321,296	1,811,431
Ordinary shares, outstanding	4,321,296	1,811,431

Consolidated Statements of Oper

Consolidated Statements of Operations - Intec Pharma Ltd. [Member] - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT EXPENSES, net	$ (6,740)	$ (26,659)
GENERAL AND ADMINISTRATIVE EXPENSES	(7,089)	(8,287)
IMPAIRMENT OF LONG-LIVED ASSETS (Note 6e(2))		(13,663)
OTHER INCOME		1,500
OPERATING LOSS	(13,829)	(47,109)
FINANCIAL INCOME (EXPENSES), net (Note 8c)	(175)	148
LOSS BEFORE INCOME TAX	(14,004)	(46,961)
INCOME TAX (Note 9)	(124)	(638)
NET LOSS	$ (14,128)	$ (47,599)
LOSS PER ORDINARY SHARE - BASIC AND DILUTED	$ (4.08)	$ (28.18)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE IN THOUSANDS	3,461	1,689

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Common Stock [Member]Intec Pharma Ltd. [Member]	Additional Paid-in Capital [Member]Intec Pharma Ltd. [Member]	Retained Earnings [Member]Intec Pharma Ltd. [Member]	Intec Pharma Ltd. [Member]	Total
Beginning balance, value at Dec. 31, 2018	$ 727	$ 194,642	$ (141,824)	$ 53,545
Shares, Outstanding, Beginning Balance at Dec. 31, 2018	1,678,469
Issuance of ordinary shares, net of issuance costs (Note 7b(1))		2,086		2,086
Stock Issued During Period Share Issuance Shares	97,226
Issuance of ordinary shares and warrants, net of issuance costs (Note 7b(3))
Stock Issued During Period, Shares, New Issues
Issuance of ordinary shares and warrants, net of issuance costs (Note 7b(4))
Number of new stock issued during the period, shares
Issuance of ordinary shares and pre-funded warrants, net of issuance costs (Note 7b(6))
Issuance of ordinary shares and pre-funded warrants, net of issuance costs (Note 7b(6)), Shares
Exercise of pre-funded warrants (Note 7b(6))
Exercise of pre-funded warrants (Note 7b(6)) (in Shares)
Exercise of warrants (Note 7b(3) and 7b(4))
Exercise of warrants (Note 7b(3) and 7b(4))
Issuance of ordinary shares per equity line agreement (Note 7b(2))
Issuance of ordinary shares per equity line agreement (Note 7b(2)) (in Shares)	30,626
Exercise of options by employees (Note 7c)		282		282
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	5,110
Share-based compensation (Note 7c)		3,221		3,221
Net loss			(47,599)	(47,599)
Ending balance, value at Dec. 31, 2019	$ 727	200,231	(189,423)	11,535
Shares, Outstanding, Ending Balance at Dec. 31, 2019	1,811,431
Issuance of ordinary shares, net of issuance costs (Note 7b(1))		421		421
Stock Issued During Period Share Issuance Shares	41,569
Issuance of ordinary shares and warrants, net of issuance costs (Note 7b(3))		5,692		5,692
Stock Issued During Period, Shares, New Issues	812,500
Issuance of ordinary shares and warrants, net of issuance costs (Note 7b(4))		4,426		4,426
Number of new stock issued during the period, shares	814,598
Issuance of ordinary shares and pre-funded warrants, net of issuance costs (Note 7b(6))		4,599		4,599
Issuance of ordinary shares and pre-funded warrants, net of issuance costs (Note 7b(6)), Shares	356,250
Exercise of pre-funded warrants (Note 7b(6))		71		71
Exercise of pre-funded warrants (Note 7b(6)) (in Shares)	356,250
Exercise of warrants (Note 7b(3) and 7b(4))		769		769
Exercise of warrants (Note 7b(3) and 7b(4))	128,698
Share-based compensation (Note 7c)		1,148		1,148
Net loss			(14,128)	(14,128)
Ending balance, value at Dec. 31, 2020	$ 727	$ 217,357	$ (203,551)	$ 14,533
Shares, Outstanding, Ending Balance at Dec. 31, 2020	4,321,296

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,128)	$ (47,599)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	1,203	854
Impairment of long-lived assets		13,663
Exchange differences on cash and cash equivalents	(162)	67
Change in right of use asset	509	967
Change in lease liabilities	(492)	(713)
Gains on marketable securities	(2)	(13)
Share-based compensation	1,148	3,221
Changes in operating asset and liabilities:
Decrease (increase) in prepaid expenses and other receivables	3,386	(747)
Decrease in deferred tax assets		281
Increase (decrease) in accounts payable and accruals	(3,060)	679
Increase in other liabilities	87	295
Net cash used in operating activities	(11,511)	(29,045)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(22)	(921)
Investment in other assets		(2,865)
Proceeds from disposal of marketable securities	772	576
Net cash provided by (used in) investing activities	750	(3,210)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of ordinary shares, net of issuance costs	421	2,086
Proceeds from issuance of ordinary shares and warrants, net of issuance costs (Note 7b(3))	5,692
Proceeds from issuance of ordinary shares and warrants, net of issuance costs (Note 7b(4))	4,426
Proceeds from issuance of ordinary shares and pre-funded warrants, net of issuance costs (Note 7b(6))	4,599
Proceeds from exercise of pre-funded warrants (Note 7b(6))	71
Proceeds from exercise of warrants (Note 7b(3) and 7b(4))	769
Proceeds from exercise of options by employees		282
Net cash provided by financing activities	15,978	2,368
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	5,217	(29,887)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	9,292	39,246
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	162	(67)
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	14,671	9,292
SUPPLEMENTARY DISCLOSURE OF CASH FLOW INFORMATION:
Taxes paid	9	75
Interest received	39	327
SUPPLEMENTARY DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Acquisition of right-of-use assets by means of lease liabilities	$ 83

NATURE OF OPERATIONS

NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
NATURE OF OPERATIONS	NOTE 1 NATURE OF OPERATIONS a. Intec Pharma Ltd. (“Intec”) is engaged in the development of proprietary technology which enables the gastric retention of certain drugs. The technology is intended to significantly improve the efficacy of the drugs and substantially reduce their side-effects or the effective doses. Intec is a limited liability public company incorporated in Israel. Intec’s ordinary shares are traded on the Nasdaq Capital Market (“Nasdaq”). In September 2017, Intec incorporated a wholly owned subsidiary in the United States of America in the State of Delaware – Intec Pharma Inc. (the “Subsidiary”, together with Intec - “the Company”). The Subsidiary was incorporated mainly to provide Intec executive and management services, including business development and investor relationship activities outside of Israel. On March 15, 2021, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Intec Parent, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Intec Parent”) that was incorporated in March 2021, Dillon Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Intec Parent (“Merger Sub”) that was incorporated in March 2021, Domestication Merger Sub Ltd., an Israeli company and a wholly owned subsidiary of Intec Parent (the “Domestication Merger Sub”) that was incorporated in March 2021 and Decoy Biosystems, Inc., a Delaware corporation (“Decoy”). Under the terms of the Merger Agreement, following the merger of the Domestication Merger Sub with and into the Company, with the Company being the surviving entity and a wholly owned subsidiary of Intec Parent (the “Domestication Merger”), and subject to satisfaction of additional closing conditions, the Merger Sub will merge with and into Decoy, with Decoy being the surviving entity and a wholly owned subsidiary of Intec Parent (the “Merger”). For more details see note 10c. b. The Company engages in research and development activities and has not yet generated revenues from operations. On July 22, 2019, the Company announced top-line results according to which its Phase III clinical trial for AP-CD/LD did not achieve its primary and secondary endpoints. Accordingly, there is no assurance that the Company’s operations will generate positive cash flows. As of December 31, 2020, the cumulative losses of the Company were approximately $ 203.6 The Company believes that it has adequate cash to fund its ongoing activities through the completion of the Merger and into the first quarter of 2022. However, changes may occur that would cause the Company to consume its existing cash prior to that time, including the costs to consummate the Merger. Prior to closing of the Merger, the Company agreed, among other things, that it would use commercially reasonable efforts to enter into one or more agreements providing for the sale, transfer or assignment or that it would otherwise take steps related to the divestment or disposal and satisfaction of liabilities of the Company’s Accordion Pill business, to be effected immediately after closing. Although the Company has entered into the Merger Agreement and intends to consummate the Merger, there is no assurance that it will be able to successfully complete the Merger on a timely basis, or at all. If, for any reason, the Merger is not consummated and the Company is unable to continue to operate its ongoing activities or identify and complete an alternative strategic transaction like the Merger, the Company may be required to dissolve and liquidate its assets. In such case, the Company would be required to pay all of its debts and contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurances as to the amount or timing of available cash left to distribute to its shareholders after paying its debts and other obligations and setting aside funds for reserves. NOTE 1 - NATURE OF OPERATIONS : In addition, the COVID-19 pandemic, that has spread globally, has resulted in significant financial market volatility and uncertainty in the past year. Many countries around the world, including in Israel and the United States, have implemented significant governmental measures to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business. The Company has implemented remote working and work place protocols for its employees in accordance with government requirements. The implementation of measures to prevent the spread of COVID-19 pandemic have resulted in disruptions to the Company’s partnering efforts which depend, in part, on attendance at in-person meetings, industry conferences and other events. It is not possible at this time to estimate the full impact that COVID-19 could have on the Company’s operation, as the impact will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain COVID-19 or treat its impact. As of the date of issuance of these consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity, or results of operations is uncertain. As a result of these uncertainties, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the issuance date of these financial statements. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. c. On September 3, 2019, the Company was notified by Nasdaq that it was not in compliance with the minimum bid price requirements for continued listing on the Nasdaq. The notification provided that the Company had 180 calendar days, or until March 2, 2020, to regain compliance. On March 3, 2020, the Company was notified that it is eligible for an additional 180 calendar day period, or until August 31, 2020, to regain compliance. As a result of tolling of compliance periods by Nasdaq, on April 17, 2020, the Company was notified that the term to regain compliance was extended until November 13, 2020. The Company implemented a 1-for-20 reverse share split the reverse share split, every 20 outstanding ordinary shares was combined into one ordinary share. 350,000,000 17,500,000 78,964,492 3,965,046 d. The Company’s effective “shelf” registration statement on Form S-3 is under General Instruction I.B.6 to Form S-3, or the Baby Shelf Rule. The amount of funds the Company can raise through primary public offerings of securities in any 12-month period using its registration statement on Form S-3 is limited to one-third of the aggregate market value of the ordinary shares held by non-affiliates of the Company.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Basis of presentation The Company’s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (‘U.S. GAAP’). b. Principles of consolidation The consolidated financial statements include the accounts of Intec and its Subsidiary. Intercompany balances and transactions have been eliminated upon consolidation. c. Use of estimates in the preparation of financial statements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to the impairment assessment on certain long-lived assets and fair value of share-based compensation. d. Functional and presentation currency The U.S. dollar (“dollar”) is the currency of the primary economic environment in which the operations of Intec and the Subsidiary are conducted. Accordingly, the functional currency of the Company is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions — exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) — historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate. e. Cash and cash equivalents The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES f. Marketable securities The Company’s marketable securities included bonds issued by the State of Israel and corporate bonds with a minimum of A rating by global rating agencies. These assets are recorded at fair value with changes recorded in the statement of operations as “financial income , g. Property and equipment 1) Property and equipment are stated at cost, net of accumulated depreciation. 2) The Company’s property and equipment are depreciated by the straight-line method on the basis of their estimated useful lives. Annual rates of depreciation are as follows: SCHEDULE OF ANNUAL RATES OF DEPRECIATION OF PROPERTY AND EQUIPMENT 2020 % Computers and peripheral equipment 33 Production and laboratory equipment 10 14 Office furniture and equipment 7 10 Leasehold improvements are depreciated by the straight-line method over the shorter of the expected lease term and the estimated useful life of the improvements. h. Impairment of long-lived assets The Company’s long-lived assets include property, equipment and long-term other assets. The Company evaluates its long-lived assets for impairment in accordance with ASC 360, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. When necessary, the Company calculates the undiscounted value of the projected cash flows associated with the asset, or asset group, and compares this estimated amount to the carrying amount. If any of its long-lived assets are considered to be impaired, the amount of impairment to be recognized is the excess of the carrying amount of the assets over its fair value. Estimates of future cash flows and timing of events for evaluating long-lived assets for impairment are based upon management’s assumptions and market conditions. Changes in assumptions or market conditions could result in a change in estimated future cash flows and the likelihood of materially different reported results. No 13.7 i. Share-based compensation The Company accounts for employees’ and directors’ share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period. The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. Performance based awards are expensed over the vesting period when the achievement of performance criteria is probable. The Company has elected to recognize forfeitures as they occur. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES j. Research and development expenses, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs and professional services. All costs associated with research and developments are expensed as incurred. Grants received from the Israel Innovation Authority, formerly known as the Office of the Chief Scientist of Israel’s Ministry of Industry, Trade and Labor (the “IIA”), were recognized when the grant becomes receivable, provided there was reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred, see note 6c. Research and development expenses, net for the year ended December 31, 2019, include participation in research and development expenses in the amount of approximately $ 1.1 no Clinical trial expenses are charged to research and development expense as incurred. The Company accrues for expenses resulting from obligations under contracts with clinical research organizations (CROs). The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company’s objective is to reflect the appropriate trial expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO, the payments are recorded as other assets, which will be recognized as expenses as services are rendered. k. Loss contingencies The Company may become involved, from time to time, in various lawsuits and legal proceedings which arise in the ordinary course of business. The Company records accruals for loss contingencies to the extent that it concludes their occurrence is probable and that the related liabilities are estimable. l. Income taxes 1) Deferred taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. 2) Uncertainty in income taxes The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES m. Loss per share Loss per share, basic and diluted, is computed on the basis of the net loss for the year divided by the weighted average number of ordinary shares outstanding during the year. Diluted loss per share is based upon the weighted average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options and warrants which are included under the treasury stock method when dilutive. The following share options were excluded from the calculation of diluted loss per ordinary share because their effect would have been anti-dilutive for the years presented (share data): SCHEDULE OF ANTI-DILUTIVE SECURITIES December 31 2020 2019 Outstanding stock options 237,288 216,255 Warrants 948,044 - n. Fair value measurement Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. o. Concentration of credit risks Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, marketable securities and certain receivables. The Company deposits cash and cash equivalents with highly rated financial institutions (Israeli banks). In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES p. Leases The Company is a lessee in several noncancelable operating leases primarily for office and operational spaces and vehicles. The Company currently has no finance leases. The Company accounts for leases in accordance with ASC Topic 842, “Leases”. The Company determines if an arrangement is a lease at inception. Right-of-use, or ROU, assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right of use assets on the consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the consolidated balance sheets. Lease expense is recognized on a straight-line basis for operating leases. The Company’s leases may include variable payments based on measures that include changes in price index. Change to index based variable lease payments is expensed in the period of the change. Variable lease payments are presented as operating expense on the consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize ROU assets or lease liabilities. Instead, the Company recognizes the lease payments for those leases in profit or loss on a straight-line basis over the lease term. The Company’s lease terms may include options of the Company as the lessee to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability if it is reasonably certain that it will exercise that option. Because the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The Company has lease agreements with lease and non-lease components and has elected the practical expedient to combine lease and non-lease components for all underlying classes of assets. All fixed payments of non-lease components are included in the measurement of lease payments, the ROU asset, and the lease liability. All variable payments for non-lease components and executory costs will be recognized and disclosed as variable lease payments. We applied the modified retrospective transition method and elected the transition option to use the effective date of January 1, 2019 as the date of initial application (“Transition Date”). Topic 842 provides for a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’, which permits not to reassess under Topic 842 its prior conclusions about lease identification, lease classification, and initial direct costs. ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES q. Newly issued accounting pronouncements New accounting pronouncements effective in future periods Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not expect that the adoption of this standard will have a material impact on its consolidated financial statements.

MARKETABLE SECURITIES

MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
MARKETABLE SECURITIES	NOTE 3 - MARKETABLE SECURITIES The Company’s marketable securities included bonds issued by the State of Israel and corporate bonds with a minimum of A rating by global rating agencies. These assets are recorded as fair value with changes recorded in the statement of operations as “financial income, net”, as the Company chose to apply the fair value option. These assets are categorized as Level 1. As of December 31, 2020, the Company had no 770 The gain, net from changes in marketable securities for the years ended December 31, 2020 and 2019 amounted to approximately $ 2 13

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
PROPERTY AND EQUIPMENT, NET	NOTE 4 - PROPERTY AND EQUIPMENT, NET SCHEDULE OF PROPERTY AND EQUIPMENT December 31 2020 2019 U.S. dollars in thousands Cost: Computers and communications equipment $ 259 $ 248 Production and laboratory equipment 7,297 7,286 Office furniture and equipment 208 208 Leasehold improvements 2,029 2,029 9,793 9,771 Less: Accumulated depreciation (8,399 ) (7,196 ) Property and equipment, net $ 1,394 $ 2,575 Depreciation expense totaled approximately $ 1,203 854

EMPLOYEE SEVERANCE BENEFITS

EMPLOYEE SEVERANCE BENEFITS	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
EMPLOYEE SEVERANCE BENEFITS	NOTE 5 - EMPLOYEE SEVERANCE BENEFITS The Company is required by Israeli law to make severance payments to Israeli employees upon dismissal or upon termination of employment in certain other circumstances. The Company operates a number of post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a separate and independent entity so that the Company has no legal or constructive obligation to pay additional contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. The fund assets are not included in the Company’s financial position. The Company operates pension and severance compensation plans subject to Section 14 of the Israeli Severance Pay Law. The plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the plans meet the definition of a defined contribution plan, as defined above. Contribution plan expenses totaled approximately $ 360 610 The Company expects contribution plan expenses in 2021 to amount to approximately $ 400

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES a. Joint venture and exclusive license agreement In June 2000, the Company engaged in a joint venture and exclusive license agreement with Yissum Research and Development Company, owned by the Hebrew University of Jerusalem (“Yissum”). Under the license agreement, the Company has been granted a perpetual and exclusive license to develop, manufacture and market products globally, which are based directly or indirectly on a patent owned by Yissum and based on the intellectual property that has been created as a result of the research that has been conducted by Yissum and financed by the Company under the license agreement. The Company is entitled to grant sub-licenses to third parties and said sub-licenses may be perpetual, and any sublicensee thereunder will not be required to assume any undertaking towards Yissum. Under the license agreement, the Company committed to act for the future development of products that are based on Yissum’s patent and on the initial research activity that was undertaken under the license agreement (the “Products”). Several pending patents have resulted from the development work done by the Company, on its behalf or on behalf of the Company and Yissum jointly. Further, the Company assumed in the license agreement all costs of submitting and managing patent applications, as well as maintaining pending and granted patents. In accordance with an amendment to the license agreement dated July 13, 2005 (which reduced royalty rates), and in exchange for the license, the Company agreed to pay 3% 15% As of the date of issuance of these consolidated financial statements, the Company has not yet begun to sell its product candidates and has not yet granted sub-licenses to any party, and, accordingly, no obligation has yet to arise to pay royalties in accordance with the license agreement. The parties are entitled to cancel the license agreement in the following cases: (a) the appointment of a liquidator or a receiver or the submission of an application for liquidation in relation to the other party, which is not cancelled within 180 days; (b) attachment proceedings, debt collecting agency proceedings and similar proceedings in connection with a significant portion of the other party’s assets; (c) the liquidation or bankruptcy of the other party; or (d) a significant breach that is not cured within 30 days from the time notice is given. If the license agreement is cancelled except in the case of its cancellation as a result of a breach by Yissum, the rights that were granted under the license will return to Yissum. In accordance with the license agreement, the agreement will remain in force until the later of the expiry of the last patent that partially underlies the Products on a global basis or 15 years from the time of the first commercial sale under the license agreement. b. Cooperation agreements As part of its operations, the Company entered into feasibility agreements with multinational companies for the development of products that combine the Company’s proprietary Accordion Pill platform technology with certain drugs for the treatment of various indications. These agreements sometimes include a mutual possibility of entering into negotiations for the acquisition of a future license for the commercial use of the products that are being developed by the multinational companies under the feasibility agreements. In addition, the multinational companies agreed to reimburse the Company for its expenses, based on milestones that are detailed in the feasibility agreements. NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES This funding is recognized in the statements of operations as a deduction from research and development expenses, as they are incurred. 1) In December 2020, the Company entered into cannabinoid research collaboration agreement with GW Research Limited (“GW”) to explore using the Accordion Pill platform for an undisclosed research program. 2) In May 2019, the Company entered into a research collaboration agreement with Merck Sharp & Dohme (“Merck”) for the development of a custom-designed Accordion Pill for one of Merck’s proprietary compounds. Under the agreement, the Company’s activities will be funded by Merck subject to the achievement of agreed milestones. In October 2020, the Company entered into a new research collaboration agreement with Merck for another compound. 3) In January 2018, the Company entered into a feasibility and option agreement with Novartis Pharmaceuticals (“Novartis”) to explore using the Accordion Pill platform for a proprietary Novartis compound. Under the agreement and the research plan, the Company’s activities were to be funded by Novartis subject to the achievement of agreed milestones. In December 2019, the Company received notice from Novartis of the termination of the agreement, since this program no longer meets Novartis’ mid to long-term strategic goals. Novartis agreed to pay to the Company $ 1.5 c. Grants from the IIA The Company has received grants from the IIA for research and development funding and therefore is subject to the provisions of the Israeli Law for the Encouragement of Research, Development and Technological Innovation in the Industry and the regulations and guidelines thereunder (the “Innovation Law”, formerly known as the Law for the Encouragement of Research and Development in Industry). Under the Innovation Law, the rate of royalties varies between 3% 5% At the time the Company received the grants, successful development of the program was not assured and, accordingly, no liability has been recognized in the financial statements. In February 2018, the Company received an approval from the IIA to manufacture its AP-CD/LD product outside of Israel. As such, the royalties to the IIA will be paid at an increased rate and up to an increased cap amount of three times the total amount of the IIA grants, plus interest accrued thereon, depending on the manufacturing volume to be performed outside Israel. The Company received from the IIA grants in the total amount of approximately NIS 42.3 11.3 NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES d. Lease Agreements: 1) The Company is a tenant under a lease agreement in respect of offices and operational spaces in Jerusalem until June 30, 2022. Rent payments are denominated in NIS and linked to the Israeli CPI. To secure the Company’s obligations to the lease agreement in Jerusalem, the Company has granted a bank guarantee to the lessor, which amounted to approximately $ 157 147 2) The Company has entered into operating lease agreements for vehicles used by its employees. The lease periods are generally for three years and the payments are linked to the Israeli CPI. To secure the terms of the lease agreements, the Company has made certain prepayments to the leasing company, representing approximately three months of lease payments. Lease expense for the years ended December 31, 2020 and 2019 was comprised of the following: SCHEDULE OF LEASE EXPENSE 2020 2019 Year ended December 31 2020 2019 U.S. dollars in thousands Operating lease expense $ 501 $ 743 Short-term lease expense 15 102 Variable lease expense - 2 Total lease expense $ 516 $ 847 Supplemental information related to leases are as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES December 31 2020 2019 U.S. dollars in thousands Operating lease right-of-use assets $ 817 $ 1,243 Current Operating lease liabilities 596 544 Non-current operating lease liabilities $ 338 $ 799 Other information: Operating cash flows from operating leases (cash paid in thousands) $ 547 $ 743 Weighted Average Remaining Lease Term (years) 1.59 2.43 Weighted Average Discount Rate of operating leases 5.40 % 5.45 % NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES Maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2020 Year Amount U.S. dollars in thousands 2021 625 2022 329 2023 22 Total lease payments 976 Less imputed interest (42 ) Total 934 e. Establishment of the Commercial Scale Production Capabilities for AP-CD/LD: 1) LTS Process Development Agreement In December 2018, the Company entered into a Process Development Agreement for Manufacturing Services with LTS for the manufacture of AP-CD/LD (the “Agreement”). Under the Agreement, the Company will bear the costs incurred by LTS to acquire the production equipment for AP-CD/LD (“Equipment”) which amounted to approximately € 6.8 7.8 In 2019, the Company performed an impairment assessment on certain of its long-lived assets which resulted an impairment charge of the Equipment in the amount of approximately $ 4.1 3.7 The Agreement also contains several termination rights, including, among others, in the cases of bankruptcy, breach by either party, change of control of either of the parties, or the sale or licensing by us of the Accordion Pill to a third party, and as of December 31, 2020 and 2019, the Company has a liability in the amount of € 2.0 2.45 2) Impairment Assessment (i) On July 22, 2019, the Company announced top-line results from its pivotal Phase III clinical for AP-CD/LD for the treatment of advanced Parkinson’s which did not meet its target endpoints. The Company determined that the Phase III clinical trial results constituted a triggering event that required the Company to evaluate its large-scale automated production line for manufacturing Accordion Pills (the “Production Line”) and Equipment net from the liability described in note 6e(1), together “AP-CD/LD Assets, net” for impairment test. For the year ended December 31, 2019, the Company recorded an impairment charge of approximately $ 13.7 NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES The following table illustrates the effect of the impairment assessment on the AP-CD/LD Assets, net, as of December 31, 2019: SCHEDULE OF IMPAIRMENT ASSESSMENT Cost/ Liability Impairment Charge Fair Value U.S. dollars in thousands Production Line $ 9,568 $ (9,568 ) $ - Equipment 7,812 (4,095 ) 3,717 Liability for LTS’s facility upgrading costs (2,244 ) - (2,244 ) AP-CD/LD Assets, net $ 15,136 $ (13,663 ) $ 1,473 The fair value was determined using the discounted cash flow method (level 3) which utilized significant estimates and assumptions surrounding the amount and timing of the projected net cash flows, which includes the probability of out-licensing the AP-CD/LD program to a third-party, the probability of obtaining FDA approval, the expected impact of competition, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, and the tax rate. (ii) As of December 31, 2020, the Company performed an additional impairment assessment on its Equipment since the uncertainty that the Company will initiate operation for commercial manufacturing in the foreseeable future. Based on this assessment, as of December 31, 2020, the fair value of the Equipment was higher than its net book value and no impairment was recorded for the year ended December 31, 2020. As of December 31, 2020, the net book value of the Equipment is approximately $ 3.7 While management believes the assumptions used in their impairment assessments are reasonable, any changes in the actual market conditions versus the assumptions used in the models could result in a change in estimated future cash flows, which may result in an additional impairment charge on Equipment in the future. f. Lawsuit In December 2019, two former directors and officers (the “plaintiffs”) filed a statement of claim with the Jerusalem District Labor Court alleging breach of contract related to a purported vesting of certain options issued to the plaintiffs pursuant to the execution of the LTS Agreement and further alleging payments due for unredeemed vacation days. The plaintiffs sought pecuniary damages of NIS 2.4 750 On February 17, 2021, the Company entered into a settlement agreement (the “Settlement Agreement”) with each of the plaintiffs, pursuant to which the Company agreed to pay to each plaintiff NIS 400 125

SHARE CAPITAL

SHARE CAPITAL	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
SHARE CAPITAL	NOTE 7 - SHARE CAPITAL a. Rights of the Company’s ordinary shares Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends. b. Changes in share capital: 1) On March 1, 2019, the Company entered into a Sales Agreement with Cowen and Company, LLC (“Cowen”) which provides that, upon the terms and subject to the conditions and limitations in the Sales Agreement, the Company may elect from time to time, to offer and sell ordinary shares through an “at-the-market” equity offering program through Cowen acting as sales agent. The issuance and sale of ordinary shares by the Company under the offering program was made pursuant to the Company’s effective “shelf” registration statement on Form S-3 filed with the SEC on March 1, 2019 and declared effective on March 28, 2019, as amended by a prospectus supplement filed on March 13, 2020. On May 4, 2020, the Company terminated the prospectus supplement, but the sales agreement remains in full force and effect. During September and December 2019, the Company sold 97,226 22.6 2.1 112 During January 2020, the Company sold 41,569 10.50 421 15 2) On December 2, 2019, the Company entered into an ordinary shares purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC (Aspire Capital) which provides that, upon the terms and subject to the conditions and limitations in the Purchase agreement, Aspire Capital is committed to purchase up to an aggregate of $ 10.0 30,626 3) On February 3, 2020, the Company completed an underwritten public offering, pursuant to which the Company issued 764,000 48,500 812,500 0.002 8.00 8.00 5.7 800 44,625 357 767,875 20,000 160 NOTE 7 - SHARE CAPITAL : 4) On May 6, 2020, the Company completed a registered direct offering, pursuant to which the Company sold and issued to certain institutional investors 814,598 6.138 407,299 4.90 five and one-half years 4.5 500 84,073 412 323,226 162,500 796 5) On July 15, 2020, the Company increased its authorized share capital from 5,000,000 17,500,000 6) On August 10, 2020, the Company completed a registered direct offering, pursuant to which the Company sold and issued to Aspire Capital Fund LLC (Aspire Capital), 356,250 7.022 356,250 6.822 0.20 4.6 330 71 4.7 c. Share-based compensation: 1) In September 2005, the Company’s board of directors approved a share option plan for grants to directors, employees and consultants (the “2005 Plan”). The 2005 plan expired in September 2015. In January 2016, the Company’s board of directors approved a new option plan (the”2015 Plan”). Originally, the maximum number of ordinary shares reserved for issuance under the 2015 Plan was 35,000 35,000 In December 2017, June 2018 and December 2019, an increase of 105,000 50,000 50,000 175,000 As of December 31, 2020, 181,027 The 2015 Plan is designed to enable the Company to grant options to purchase ordinary shares under various and different tax regimes including, without limitation: pursuant and subject to Section 102 of the Israeli Tax Ordinance and pursuant and subject to Section 3(i) of the Israeli Tax Ordinance. NOTE 7 - SHARE CAPITAL : The awards may be exercised after vesting and in accordance with vesting schedules which will be determined by the Company’s board of directors for each grant. The maximum term of the awards is 10 The Company’s management uses the contractual term or its expectations, as applicable, of each option as its expected life. The expected term of the options granted represents the period that granted options are expected to remain outstanding. 2) On August 22, 2019, the Company reduced the exercise price of 63,183 previously granted to employees to $ 8.94 253 pricing options model using the following assumptions: risk free interest rate of 1.5% 99% 122% 2.6 4.4 years and dividend yield of 0% 62 3) During the years ended December 31, 2020 and December 31, 2019, the Company granted options to employees and directors as follows: SCHEDULE OF OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS Year ended December 31, 2020 Number of options granted Exercise price Vesting period Expiration Employees 85,000 $ 6.15 8.57 1.29 3 7 Directors 10,000 $ 6.15 3 7 Year ended December 31, 2019 Number of options granted Exercise price range Vesting period Expiration Employees 73,250 $ 8.94 152.8 3 7 Directors 7,000 $ 12.4 97.2 3 7 The weighted average fair value of options granted during the years was generally estimated by using the Black-Scholes option-pricing model as follows: SCHEDULE OF WEIGHTED AVERAGE FAIR VALUE OF OPTIONS GRANTED Year ended December 31 2020 2019 Weighted average fair value $ 4.38 $ 55.28 NOTE 7 - SHARE CAPITAL : The underlying data used for computing the fair value of the options are as follows: SCHEDULE OF UNDERLYING DATA USED FOR COMPUTING THE FAIR VALUE OF OPTIONS Year ended December 31 2020 2019 Value of ordinary share $ 5.60 6.20 $ 10.2 149.2 Dividend yield 0 % 0 % Expected volatility 102.58 110.4 % 53.32 100.04 % Risk-free interest rate 0.28 1.42 % 1.65 2.57 % Expected term 5 5 The following table summarizes the number of options outstanding with exercise price in NIS, which were granted under the 2005 Plan, for the years ended December 31, 2020 and December 31, 2019, and related information: SCHEDULE OF NUMBER OF OPTIONS OUTSTANDING Employees and directors Consultants Number of options NIS (1) Number of options NIS (1) Outstanding at January 1, 2019 14,773 550.4 402 10.0 Exercised (1 ) 10.0 (127 ) 10.0 Forfeited (4,295 ) 465.0 - - Expired (6,343 ) 437.8 (275 ) 10.0 Outstanding at December 31, 2019 4,134 812.0 - - Outstanding at December 31, 2019 4,134 812.0 - - Forfeited - - - - Expired (4,134 ) 812.0 - - Outstanding at December 31, 2020 - - - - The following table summarizes the number of options outstanding with exercise price in USD, which were granted under the 2015 Plan, for the years ended December 31, 2020 and December 31, 2019, and related information: Employees and directors Number of options USD (2) Outstanding at January 1, 2019 156,909 117.0 Granted 80,250 69.0 Exercised (4,982 ) 56.6 Forfeited (22,537 ) 80.0 Expired (13,495 ) 140.0 Outstanding at December 31, 2019 196,145 82.6 Outstanding at December 31, 2019 196,145 82.6 Granted 95,000 7.09 Forfeited (18,249 ) 39.47 Expired (9,816 ) 41.18 Outstanding at December 31, 2020 263,080 59.87 (1) Weighted average price in NIS per share. (2) Weighted average price in USD per share. NOTE 7 - SHARE CAPITAL : The following table summarizes information concerning outstanding and exercisable options with exercise prices in USD as of December 31, 2020: SCHEDULE OF INFORMATION CONCERNING OUTSTANDING AND EXERCISABLE OPTIONS December 31, 2020 Options outstanding Options exercisable Exercise price per share (USD) Number of options outstanding at the end of year Weighted average remaining contractual life Number of options exercisable at the end of year Weighted average remaining contractual life 6.15 6.67 60,750 6.64 - - 8.58 8.94 60,416 4.93 28,810 3.91 11.1 18.0 21,000 5.71 8,668 5.71 70.52 11,224 5.37 11,224 5.37 82.8 89.3 20,440 5.05 14,692 4.95 97.2 4,000 5.49 1,996 5.49 103.8 109.2 21,750 4.85 21,188 4.87 120.0 122.0 11,542 0.60 11,542 0.60 134.0 19,000 6.95 19,000 6.95 152.6 152.8 22,958 4.42 14,207 3.98 171.2 10,000 6.91 10,000 6.91 263,080 141,327 As of December 31, 2020, the total outstanding and exercisable options have no intrinsic value. The following table illustrates the effect of share-based compensation on the statements of operations: SCHEDULE OF EFFECT OF SHARE-BASED COMPENSATION Year ended December 31 2020 2019 U.S. dollars in thousands Research and development expenses, net $ 289 $ 1,634 General and administrative expenses 859 1,587 $ 1,148 $ 3,221

SUPPLEMENTARY FINANCIAL STATEME

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:	NOTE 8 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION: Balance sheets: SCHEDULE OF SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION 2020 2019 December 31 2020 2019 U.S. dollars in thousands a. Prepaid expenses and other receivable: Institutions $ 25 $ 1,836 Termination fee, Novartis (see note 6b(1)) - 1,500 Prepaid expenses 212 194 Advances to suppliers - 3 Interest receivable - 3 Other receivables 60 147 Prepaid expenses and other receivable $ 297 $ 3,683 b. Accounts payable and accruals - other: Expenses payable 2,859 2,838 Salary and related expenses, including social security and other taxes 1,057 1,277 Current operating lease liabilities (see note 6d) 596 544 Accrual for vacation days and recreation pay for employees 180 154 Other 274 22 Accounts payable and accruals - other $ 4,966 $ 4,835 Statements of operations: c. Financial income (expenses), net: 2020 2019 Year ended December 31 2020 2019 U.S. dollars in thousands Financial income: Interest on cash and cash equivalents $ 39 $ 330 Gains from changes in fair value of marketable securities 2 13 Financial income $ 41 $ 343 Financial expenses - Loss from changes in exchange rates $ (206 ) $ (180 ) Bank fees (10 ) (15 ) Financial expenses $ (216 ) $ (195 ) Financial income (expenses), net $ (175 ) $ 148

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
TAXES ON INCOME	NOTE 9 - TAXES ON INCOME a. Tax rates: 1) Income from Israel is taxed according to the Israeli tax laws. Capital gains are taxed at the standard corporate tax rate. Israeli tax rate relevant to the Company is 23 2) Income of the subsidiary is taxed according to the federal tax laws in the US and the relevant state laws. The relevant U.S. statutory tax rates for 2020 and 2019 were 21 7 The U.S. Tax Cuts and Jobs Act (“Tax Act”) was enacted on December 22, 2017 and introduced significant changes to U.S. income tax law. Effective in 2018, the Tax Act reduced the U.S. federal statutory tax rate from 35 21 b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 in Israel (the “ECI Law”) Under the ECI Law, Intec may be entitled to tax benefits, by virtue of its status as a “Benefited Enterprise”, which was awarded to Intec in October 2007. Intec received the status of a “plant under establishment” in Development Area A in a tax-exempt track, subject to compliance with the applicable requirements by the Law. As of December 31, 2020, Intec has not yet generated operating income that will allow it to benefit from the tax benefits under the ECI Law. The tax benefits under the ECI Law will apply for a period of up to ten years from the first year in which taxable income will be generated and are scheduled to expire at the end of 2023. c. Tax assessments Intec has tax assessments that are considered to be final through tax year 2016. d. Losses for tax purposes carried forward to future years As of December 31, 2020, Intec had approximately $ 173.6 e. Subsidiary tax expenses During 2020 and 2019, the Subsidiary incurred a tax expense in the amount of approximately $ 124 638 87 562 NOTE 9 - TAXES ON INCOME : f. Deferred income taxes: SCHEDULE OF DEFERRED INCOME TAXES 2020 2019 December 31 2020 2019 U.S. dollars in thousands In respect of: Net operating loss carry forward $ 39,924 $ 33,316 Research and Development expenses 2,910 6,209 Impairment of long-lived assets 3,143 3,143 Issuance costs 274 216 Other 1,246 1,138 Less—valuation allowance (47,497 ) (44,022 ) Net deferred tax assets $ - $ - The change in valuation allowance for the years ended December 31, 2020 and 2019 were as follows: SCHEDULE OF CHANGE IN VALUATION ALLOWANCE Year ended December 31 2020 2019 U.S. dollars in thousands Balance at the beginning of the year $ 44,022 $ 32,684 Changes during the year 3,475 11,338 Balance at the end of the year $ 47,497 $ 44,022 g. Loss before income tax: The components of loss before income tax are as follows: SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAX 2020 2019 Year ended December 31 2020 2019 U.S. dollars in thousands Income (loss) before income tax: Intec $ (14,180 ) $ (47,331 ) Subsidiary 176 370 Income (loss) before income tax $ (14,004 ) $ (46,961 ) h. Current taxes on income The main reconciling item between the statutory tax rates of the Company and the effective rate is the provision for valuation allowance in respect of tax benefits from carryforward tax losses and research and development expenses due to the uncertainty of the realization of such tax benefits. i. ASC No. 740, Income Taxes, requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The following table summarizes the activity of the Company unrecognized tax benefits: SCHEDULE OF UNRECOGNIZED TAX BENEFITS Year ended December 31 2020 2019 U.S. dollars in thousands Balance at the beginning of the year $ 604 $ 309 Increase in uncertain tax positions for the current year 87 295 Balance at the end of the year $ 691 $ 604 The Company does not expect unrecognized tax expenses to change significantly over the next 12 months.

EVENTS SUBSEQUENT TO DECEMBER 3

EVENTS SUBSEQUENT TO DECEMBER 31, 2020	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
EVENTS SUBSEQUENT TO DECEMBER 31, 2020	NOTE 10 - EVENTS SUBSEQUENT TO DECEMBER 31, 2020 a. In February 2021, warrants to purchase 182,500 956 b. In February 2021, the Company entered into a non-binding term sheet for the sale or license of the AP-CD/LD program to an undisclosed third party and are currently negotiating the terms of a definitive agreement. There is no assurance that this will result in a definitive agreement. c. On March 15, 2021, the Company entered into a Merger Agreement with Intec Parent, Merger Sub, Domestication Merger Sub, and Decoy, pursuant to which, following the Domestication Merger, and upon satisfaction of additional closing conditions, the Merger Sub will merge with and into Decoy, with Decoy being the surviving entity and a wholly owned subsidiary of Intec Parent. If the Merger is completed then the business of Decoy will become the business of Intec Parent. Under the exchange ratio formula in the Merger Agreement, without taking into consideration the effect of the respective levels of cash and liabilities of each of the Company and Decoy, which will result in an adjustment to such exchange ratio, 75 % of the aggregate number of the outstanding securities of Intec Parent (based on a valuation of $ 30 million), and the securityholders of the Company immediately before the Domestication Merger are expected to own approximately 25 % of the aggregate number of the outstanding securities of Intec Parent (based on a valuation of $ 10 million), calculated on a fully-diluted basis. The actual allocation will be subject to adjustment based on, among other things, Decoy’s and the Company’s net cash balance (including, in the case of the Company, any proceeds from any disposition of the Company’s Accordion Pill business), subject to certain exceptions. As further described below, the Closing is also conditioned on completion of the Domestication Merger and on a financing by the Company or Intec Parent, which will dilute securityholders of both the Company and Decoy on a pro-rata basis. The Merger Agreement contains customary representations, warranties and covenants made by each of the Company and Decoy, including covenants relating to (i) the conduct of their respective businesses prior to the Closing, (ii) the preparation and filing of a registration statement on Form S-4 registering the Merger Shares and the shares of Intec Parent Common Stock to be issued in connection with the Domestication Merger (the “Registration Statement”) and the preparation and/or filing, as applicable, of a proxy statement/information statement for the special meeting or approval by written consent, as applicable, of shareholders of each of the Company and Decoy, (iii) holding a meeting or approval by written consent, as applicable, of shareholders of each of the Company and Decoy to obtain their requisite approvals in connection with the Domestication Merger and Merger, as applicable, including, among other approvals, the approval by the Company’s shareholders of the issuance of the Merger Shares, and (iv) subject to certain exceptions, the recommendation of the board of directors of each party to the Merger Agreement to its shareholders that such approvals be given. Consummation of the Merger is subject to certain closing conditions, including, among other things, (i) consummation of the Domestication Merger, (ii) approval of certain matters related to the Merger by the shareholders of the Company and approval of the Merger by the stockholders of Decoy, (iii) the effectiveness of the Registration Statement, (iv) the continued listing of the Company’s ordinary shares on the Nasdaq Capital Market (and following the Domestication Merger, the shares of Intec Parent Common Stock) and the authorization for listing on the Nasdaq Capital Market of the Merger Shares, (v) the receipt of a tax ruling from the Israel Tax Authority with respect to the Domestication Merger, (vi) disposition of the Company’s Accordion Pill business, as further described below, and (vii) a closing financing by the Company or Intec Parent such that upon Closing of the Merger (taking account of the proceeds to be received with respect to such financing), the combined net cash of Intec Parent shall be not less than $ 30 50 NOTE 10 - EVENTS SUBSEQUENT TO DECEMBER 31, 2020 Closing. The Merger Agreement requires the Company to convene a shareholders’ meeting for purposes of obtaining the necessary shareholder approvals required in connection with the Merger. The Merger Agreement contains certain termination rights for both the Company and Decoy, including, but not limited to, the right of the Company and Decoy to terminate the Merger Agreement by mutual written consent or if a court of competent jurisdiction or other Governmental Body (as defined in the Merger Agreement) has issued a final and nonappealable order, decree or ruling, or has taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Merger. In addition, either the Company or Decoy may terminate the Merger Agreement if the Merger is not consummated on or before the date that is 155 days following the delivery of the Decoy audited financial statements for the fiscal years ended December 31, 2020 and 2019, which date may be extended in certain circumstances. In connection with the termination of the Merger Agreement, under specified circumstances, Decoy may be required to pay to the Company a break-up fee of $ 1,000,000 350,000 As set forth in the Merger Agreement, prior to the date of the closing date (the “Closing Date”), the Company shall re-domesticate as a Delaware corporation by merging with and into the Domestication Merger Sub, with the Company surviving the merger and becoming a wholly owned subsidiary of Intec Parent. In connection with the Domestication Merger, all the Company’s ordinary shares, having no par value per share (the “Intec Israel Shares”), outstanding immediately prior to the Domestication Merger, will convert, on a one-for-one basis, into shares of Intec Parent Common Stock and all options and warrants to purchase Intec Israel Shares outstanding immediately prior to the Domestication Merger will be exchanged for equivalent securities of Intec Parent. In accordance with the terms of the Merger Agreement, the Company agreed that prior to the Closing Date it would use commercially reasonable efforts to enter into one or more agreements providing for the sale, transfer or assignment, or that it would otherwise take steps related to the divestment or disposal and satisfaction of liabilities of, the Company’s Accordion Pill business, to be effected immediately after the Closing. NOTE 11 - EVENTS SUBSEQUENT TO DECEMBER 31, 2020 a. As of March 31, 2021, the Company has transferred $ 650 350 b. In April 2021, the Company sold to Aspire Capital Fund LLC (“Aspire Capital”) 319,393 1.2 c. Four lawsuits have been filed against the Company and its board of directors in federal court: St Hilarie v. Intec Pharma Ltd, et al. ); Minh Tran v. Intec Pharma Ltd., et al Craig Davidson v. Intec Pharma Ltd. et al. Jordan Sanchez Figueroa v. Intec Pharma Ltd. et al Davidson

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies) - Intec Pharma Ltd. [Member]	12 Months Ended
	Dec. 31, 2020
Basis of presentation	a. Basis of presentation The Company’s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (‘U.S. GAAP’).
Principles of consolidation	b. Principles of consolidation The consolidated financial statements include the accounts of Intec and its Subsidiary. Intercompany balances and transactions have been eliminated upon consolidation.
Use of estimates in the preparation of financial statements	c. Use of estimates in the preparation of financial statements The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to the impairment assessment on certain long-lived assets and fair value of share-based compensation.
Functional and presentation currency	d. Functional and presentation currency The U.S. dollar (“dollar”) is the currency of the primary economic environment in which the operations of Intec and the Subsidiary are conducted. Accordingly, the functional currency of the Company is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions — exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) — historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.
Cash and cash equivalents	e. Cash and cash equivalents The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.
Marketable securities	f. Marketable securities The Company’s marketable securities included bonds issued by the State of Israel and corporate bonds with a minimum of A rating by global rating agencies. These assets are recorded at fair value with changes recorded in the statement of operations as “financial income ,
Property and equipment	g. Property and equipment 1) Property and equipment are stated at cost, net of accumulated depreciation. 2) The Company’s property and equipment are depreciated by the straight-line method on the basis of their estimated useful lives. Annual rates of depreciation are as follows: SCHEDULE OF ANNUAL RATES OF DEPRECIATION OF PROPERTY AND EQUIPMENT 2020 % Computers and peripheral equipment 33 Production and laboratory equipment 10 14 Office furniture and equipment 7 10 Leasehold improvements are depreciated by the straight-line method over the shorter of the expected lease term and the estimated useful life of the improvements.
Impairment of long-lived assets	h. Impairment of long-lived assets The Company’s long-lived assets include property, equipment and long-term other assets. The Company evaluates its long-lived assets for impairment in accordance with ASC 360, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. When necessary, the Company calculates the undiscounted value of the projected cash flows associated with the asset, or asset group, and compares this estimated amount to the carrying amount. If any of its long-lived assets are considered to be impaired, the amount of impairment to be recognized is the excess of the carrying amount of the assets over its fair value. Estimates of future cash flows and timing of events for evaluating long-lived assets for impairment are based upon management’s assumptions and market conditions. Changes in assumptions or market conditions could result in a change in estimated future cash flows and the likelihood of materially different reported results. No 13.7
Share-based compensation	i. Share-based compensation The Company accounts for employees’ and directors’ share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period. The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. Performance based awards are expensed over the vesting period when the achievement of performance criteria is probable. The Company has elected to recognize forfeitures as they occur.
Research and development expenses, net	j. Research and development expenses, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing costs and professional services. All costs associated with research and developments are expensed as incurred. Grants received from the Israel Innovation Authority, formerly known as the Office of the Chief Scientist of Israel’s Ministry of Industry, Trade and Labor (the “IIA”), were recognized when the grant becomes receivable, provided there was reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred, see note 6c. Research and development expenses, net for the year ended December 31, 2019, include participation in research and development expenses in the amount of approximately $ 1.1 no Clinical trial expenses are charged to research and development expense as incurred. The Company accrues for expenses resulting from obligations under contracts with clinical research organizations (CROs). The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. The Company’s objective is to reflect the appropriate trial expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO, the payments are recorded as other assets, which will be recognized as expenses as services are rendered.
Loss contingencies	k. Loss contingencies The Company may become involved, from time to time, in various lawsuits and legal proceedings which arise in the ordinary course of business. The Company records accruals for loss contingencies to the extent that it concludes their occurrence is probable and that the related liabilities are estimable.
Income taxes	l. Income taxes 1) Deferred taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. 2) Uncertainty in income taxes The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement.
Loss per share	m. Loss per share Loss per share, basic and diluted, is computed on the basis of the net loss for the year divided by the weighted average number of ordinary shares outstanding during the year. Diluted loss per share is based upon the weighted average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options and warrants which are included under the treasury stock method when dilutive. The following share options were excluded from the calculation of diluted loss per ordinary share because their effect would have been anti-dilutive for the years presented (share data): SCHEDULE OF ANTI-DILUTIVE SECURITIES December 31 2020 2019 Outstanding stock options 237,288 216,255 Warrants 948,044 -
Fair value measurement	n. Fair value measurement Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Concentration of credit risks	o. Concentration of credit risks Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, marketable securities and certain receivables. The Company deposits cash and cash equivalents with highly rated financial institutions (Israeli banks). In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.
Leases	p. Leases The Company is a lessee in several noncancelable operating leases primarily for office and operational spaces and vehicles. The Company currently has no finance leases. The Company accounts for leases in accordance with ASC Topic 842, “Leases”. The Company determines if an arrangement is a lease at inception. Right-of-use, or ROU, assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term as of the commencement date. Operating lease ROU assets are presented as operating lease right of use assets on the consolidated balance sheets. The current portion of operating lease liabilities is included in other current liabilities and the long-term portion is presented separately as operating lease liabilities on the consolidated balance sheets. Lease expense is recognized on a straight-line basis for operating leases. The Company’s leases may include variable payments based on measures that include changes in price index. Change to index based variable lease payments is expensed in the period of the change. Variable lease payments are presented as operating expense on the consolidated statements of operations in the same line item as expense arising from fixed lease payments. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize ROU assets or lease liabilities. Instead, the Company recognizes the lease payments for those leases in profit or loss on a straight-line basis over the lease term. The Company’s lease terms may include options of the Company as the lessee to extend the lease. The lease extensions are included in the measurement of the right of use asset and lease liability if it is reasonably certain that it will exercise that option. Because the Company’s leases do not provide an implicit rate of return, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments on an individual lease basis. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The Company has lease agreements with lease and non-lease components and has elected the practical expedient to combine lease and non-lease components for all underlying classes of assets. All fixed payments of non-lease components are included in the measurement of lease payments, the ROU asset, and the lease liability. All variable payments for non-lease components and executory costs will be recognized and disclosed as variable lease payments. We applied the modified retrospective transition method and elected the transition option to use the effective date of January 1, 2019 as the date of initial application (“Transition Date”). Topic 842 provides for a number of optional practical expedients in transition. The Company elected the ‘package of practical expedients’, which permits not to reassess under Topic 842 its prior conclusions about lease identification, lease classification, and initial direct costs. ROU assets for operating leases are periodically reviewed for impairment losses under ASC 360-10, “Property, Plant, and Equipment”, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize.
Newly issued accounting pronouncements	q. Newly issued accounting pronouncements New accounting pronouncements effective in future periods Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not expect that the adoption of this standard will have a material impact on its consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables) - Intec Pharma Ltd. [Member]	12 Months Ended
	Dec. 31, 2020
SCHEDULE OF ANNUAL RATES OF DEPRECIATION OF PROPERTY AND EQUIPMENT	Annual rates of depreciation are as follows: SCHEDULE OF ANNUAL RATES OF DEPRECIATION OF PROPERTY AND EQUIPMENT 2020 % Computers and peripheral equipment 33 Production and laboratory equipment 10 14 Office furniture and equipment 7 10
SCHEDULE OF ANTI-DILUTIVE SECURITIES	The following share options were excluded from the calculation of diluted loss per ordinary share because their effect would have been anti-dilutive for the years presented (share data): SCHEDULE OF ANTI-DILUTIVE SECURITIES December 31 2020 2019 Outstanding stock options 237,288 216,255 Warrants 948,044 -

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
SCHEDULE OF PROPERTY AND EQUIPMENT	SCHEDULE OF PROPERTY AND EQUIPMENT December 31 2020 2019 U.S. dollars in thousands Cost: Computers and communications equipment $ 259 $ 248 Production and laboratory equipment 7,297 7,286 Office furniture and equipment 208 208 Leasehold improvements 2,029 2,029 9,793 9,771 Less: Accumulated depreciation (8,399 ) (7,196 ) Property and equipment, net $ 1,394 $ 2,575 Depreciation expense totaled approximately $ 1,203 854

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Tables) - Intec Pharma Ltd. [Member]	12 Months Ended
	Dec. 31, 2020
SCHEDULE OF LEASE EXPENSE	Lease expense for the years ended December 31, 2020 and 2019 was comprised of the following: SCHEDULE OF LEASE EXPENSE 2020 2019 Year ended December 31 2020 2019 U.S. dollars in thousands Operating lease expense $ 501 $ 743 Short-term lease expense 15 102 Variable lease expense - 2 Total lease expense $ 516 $ 847
SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES	Supplemental information related to leases are as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES December 31 2020 2019 U.S. dollars in thousands Operating lease right-of-use assets $ 817 $ 1,243 Current Operating lease liabilities 596 544 Non-current operating lease liabilities $ 338 $ 799 Other information: Operating cash flows from operating leases (cash paid in thousands) $ 547 $ 743 Weighted Average Remaining Lease Term (years) 1.59 2.43 Weighted Average Discount Rate of operating leases 5.40 % 5.45 %
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2020 Year Amount U.S. dollars in thousands 2021 625 2022 329 2023 22 Total lease payments 976 Less imputed interest (42 ) Total 934
SCHEDULE OF IMPAIRMENT ASSESSMENT	The following table illustrates the effect of the impairment assessment on the AP-CD/LD Assets, net, as of December 31, 2019: SCHEDULE OF IMPAIRMENT ASSESSMENT Cost/ Liability Impairment Charge Fair Value U.S. dollars in thousands Production Line $ 9,568 $ (9,568 ) $ - Equipment 7,812 (4,095 ) 3,717 Liability for LTS’s facility upgrading costs (2,244 ) - (2,244 ) AP-CD/LD Assets, net $ 15,136 $ (13,663 ) $ 1,473

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables) - Intec Pharma Ltd. [Member]	12 Months Ended
	Dec. 31, 2020
SCHEDULE OF OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	3) During the years ended December 31, 2020 and December 31, 2019, the Company granted options to employees and directors as follows: SCHEDULE OF OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS Year ended December 31, 2020 Number of options granted Exercise price Vesting period Expiration Employees 85,000 $ 6.15 8.57 1.29 3 7 Directors 10,000 $ 6.15 3 7 Year ended December 31, 2019 Number of options granted Exercise price range Vesting period Expiration Employees 73,250 $ 8.94 152.8 3 7 Directors 7,000 $ 12.4 97.2 3 7
SCHEDULE OF WEIGHTED AVERAGE FAIR VALUE OF OPTIONS GRANTED	The weighted average fair value of options granted during the years was generally estimated by using the Black-Scholes option-pricing model as follows: SCHEDULE OF WEIGHTED AVERAGE FAIR VALUE OF OPTIONS GRANTED Year ended December 31 2020 2019 Weighted average fair value $ 4.38 $ 55.28
SCHEDULE OF UNDERLYING DATA USED FOR COMPUTING THE FAIR VALUE OF OPTIONS	The underlying data used for computing the fair value of the options are as follows: SCHEDULE OF UNDERLYING DATA USED FOR COMPUTING THE FAIR VALUE OF OPTIONS Year ended December 31 2020 2019 Value of ordinary share $ 5.60 6.20 $ 10.2 149.2 Dividend yield 0 % 0 % Expected volatility 102.58 110.4 % 53.32 100.04 % Risk-free interest rate 0.28 1.42 % 1.65 2.57 % Expected term 5 5
SCHEDULE OF NUMBER OF OPTIONS OUTSTANDING	The following table summarizes the number of options outstanding with exercise price in NIS, which were granted under the 2005 Plan, for the years ended December 31, 2020 and December 31, 2019, and related information: SCHEDULE OF NUMBER OF OPTIONS OUTSTANDING Employees and directors Consultants Number of options NIS (1) Number of options NIS (1) Outstanding at January 1, 2019 14,773 550.4 402 10.0 Exercised (1 ) 10.0 (127 ) 10.0 Forfeited (4,295 ) 465.0 - - Expired (6,343 ) 437.8 (275 ) 10.0 Outstanding at December 31, 2019 4,134 812.0 - - Outstanding at December 31, 2019 4,134 812.0 - - Forfeited - - - - Expired (4,134 ) 812.0 - - Outstanding at December 31, 2020 - - - - The following table summarizes the number of options outstanding with exercise price in USD, which were granted under the 2015 Plan, for the years ended December 31, 2020 and December 31, 2019, and related information: Employees and directors Number of options USD (2) Outstanding at January 1, 2019 156,909 117.0 Granted 80,250 69.0 Exercised (4,982 ) 56.6 Forfeited (22,537 ) 80.0 Expired (13,495 ) 140.0 Outstanding at December 31, 2019 196,145 82.6 Outstanding at December 31, 2019 196,145 82.6 Granted 95,000 7.09 Forfeited (18,249 ) 39.47 Expired (9,816 ) 41.18 Outstanding at December 31, 2020 263,080 59.87 (1) Weighted average price in NIS per share. (2) Weighted average price in USD per share.
SCHEDULE OF INFORMATION CONCERNING OUTSTANDING AND EXERCISABLE OPTIONS	The following table summarizes information concerning outstanding and exercisable options with exercise prices in USD as of December 31, 2020: SCHEDULE OF INFORMATION CONCERNING OUTSTANDING AND EXERCISABLE OPTIONS December 31, 2020 Options outstanding Options exercisable Exercise price per share (USD) Number of options outstanding at the end of year Weighted average remaining contractual life Number of options exercisable at the end of year Weighted average remaining contractual life 6.15 6.67 60,750 6.64 - - 8.58 8.94 60,416 4.93 28,810 3.91 11.1 18.0 21,000 5.71 8,668 5.71 70.52 11,224 5.37 11,224 5.37 82.8 89.3 20,440 5.05 14,692 4.95 97.2 4,000 5.49 1,996 5.49 103.8 109.2 21,750 4.85 21,188 4.87 120.0 122.0 11,542 0.60 11,542 0.60 134.0 19,000 6.95 19,000 6.95 152.6 152.8 22,958 4.42 14,207 3.98 171.2 10,000 6.91 10,000 6.91 263,080 141,327
SCHEDULE OF EFFECT OF SHARE-BASED COMPENSATION	The following table illustrates the effect of share-based compensation on the statements of operations: SCHEDULE OF EFFECT OF SHARE-BASED COMPENSATION Year ended December 31 2020 2019 U.S. dollars in thousands Research and development expenses, net $ 289 $ 1,634 General and administrative expenses 859 1,587 $ 1,148 $ 3,221

SUPPLEMENTARY FINANCIAL STATE_2

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION: (Tables)	12 Months Ended
	Dec. 31, 2020
Intec Pharma Ltd. [Member]
SCHEDULE OF SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	Balance sheets: SCHEDULE OF SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION 2020 2019 December 31 2020 2019 U.S. dollars in thousands a. Prepaid expenses and other receivable: Institutions $ 25 $ 1,836 Termination fee, Novartis (see note 6b(1)) - 1,500 Prepaid expenses 212 194 Advances to suppliers - 3 Interest receivable - 3 Other receivables 60 147 Prepaid expenses and other receivable $ 297 $ 3,683 b. Accounts payable and accruals - other: Expenses payable 2,859 2,838 Salary and related expenses, including social security and other taxes 1,057 1,277 Current operating lease liabilities (see note 6d) 596 544 Accrual for vacation days and recreation pay for employees 180 154 Other 274 22 Accounts payable and accruals - other $ 4,966 $ 4,835 Statements of operations: c. Financial income (expenses), net: 2020 2019 Year ended December 31 2020 2019 U.S. dollars in thousands Financial income: Interest on cash and cash equivalents $ 39 $ 330 Gains from changes in fair value of marketable securities 2 13 Financial income $ 41 $ 343 Financial expenses - Loss from changes in exchange rates $ (206 ) $ (180 ) Bank fees (10 ) (15 ) Financial expenses $ (216 ) $ (195 ) Financial income (expenses), net $ (175 ) $ 148

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables) - Intec Pharma Ltd. [Member]	12 Months Ended
	Dec. 31, 2020
SCHEDULE OF DEFERRED INCOME TAXES	f. Deferred income taxes: SCHEDULE OF DEFERRED INCOME TAXES 2020 2019 December 31 2020 2019 U.S. dollars in thousands In respect of: Net operating loss carry forward $ 39,924 $ 33,316 Research and Development expenses 2,910 6,209 Impairment of long-lived assets 3,143 3,143 Issuance costs 274 216 Other 1,246 1,138 Less—valuation allowance (47,497 ) (44,022 ) Net deferred tax assets $ - $ -
SCHEDULE OF CHANGE IN VALUATION ALLOWANCE	The change in valuation allowance for the years ended December 31, 2020 and 2019 were as follows: SCHEDULE OF CHANGE IN VALUATION ALLOWANCE Year ended December 31 2020 2019 U.S. dollars in thousands Balance at the beginning of the year $ 44,022 $ 32,684 Changes during the year 3,475 11,338 Balance at the end of the year $ 47,497 $ 44,022
SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAX	The components of loss before income tax are as follows: SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAX 2020 2019 Year ended December 31 2020 2019 U.S. dollars in thousands Income (loss) before income tax: Intec $ (14,180 ) $ (47,331 ) Subsidiary 176 370 Income (loss) before income tax $ (14,004 ) $ (46,961 )
SCHEDULE OF UNRECOGNIZED TAX BENEFITS	The following table summarizes the activity of the Company unrecognized tax benefits: SCHEDULE OF UNRECOGNIZED TAX BENEFITS Year ended December 31 2020 2019 U.S. dollars in thousands Balance at the beginning of the year $ 604 $ 309 Increase in uncertain tax positions for the current year 87 295 Balance at the end of the year $ 691 $ 604

NATURE OF OPERATIONS (Details N

NATURE OF OPERATIONS (Details Narrative) - Intec Pharma Ltd. [Member] - USD ($) $ in Millions	Oct. 30, 2020	Dec. 31, 2020	Oct. 29, 2020	Dec. 31, 2019
Accumulated deficit		$ 203.6
Reverse share split, description	1-for-20 reverse share split
Ordinary shares, authorized		17,500,000		5,000,000
Ordinary shares, outstanding		4,321,296		1,811,431
Reverse Stock Split [Member]
Ordinary shares, authorized	17,500,000		350,000,000
Ordinary shares, outstanding	3,965,046		78,964,492

SCHEDULE OF ANNUAL RATES OF DEP

SCHEDULE OF ANNUAL RATES OF DEPRECIATION OF PROPERTY AND EQUIPMENT (Details) - Intec Pharma Ltd. [Member]	12 Months Ended
	Dec. 31, 2020
Computers and Communications Equipment [Member]
Annual rates of depreciation	33.00%
Other Machinery and Equipment [Member] | Minimum [Member]
Annual rates of depreciation	10.00%
Other Machinery and Equipment [Member] | Maximum [Member]
Annual rates of depreciation	14.00%
Office Equipment [Member] | Minimum [Member]
Annual rates of depreciation	7.00%
Office Equipment [Member] | Maximum [Member]
Annual rates of depreciation	10.00%

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details) - Intec Pharma Ltd. [Member] - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Outstanding Stock Options [Member]
Anti-dilutive securities	237,288	216,255
Warrants [Member]
Anti-dilutive securities	948,044

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Impairment on long-lived assets	$ 0	$ 13,700
Participation in research and development expenses	$ 0	$ 1,100

MARKETABLE SECURITIES (Details

MARKETABLE SECURITIES (Details Narrative) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Marketable securities	$ 0	$ 770
Gain, net from changes in marketable securities	$ 2	$ 13

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Cost	$ 9,793	$ 9,771
Less: Accumulated depreciation	(8,399)	(7,196)
Property and equipment, net	1,394	2,575
Computer Equipment [Member]
Cost	259	248
Other Machinery and Equipment [Member]
Cost	7,297	7,286
Office Equipment [Member]
Cost	208	208
Leasehold Improvements [Member]
Cost	$ 2,029	$ 2,029

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Intec Pharma Ltd. [Member]
Depreciation expense	$ 1,203	$ 854

EMPLOYEE SEVERANCE BENEFITS (De

EMPLOYEE SEVERANCE BENEFITS (Details Narrative) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Severance payment expenses	$ 360	$ 610
Expected deposit with respect to employee's severance benefits	$ 400

SCHEDULE OF LEASE EXPENSE (Deta

SCHEDULE OF LEASE EXPENSE (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating lease expense	$ 501	$ 743
Short-term lease expense	15	102
Variable lease expense		2
Total lease expense	$ 516	$ 847

SCHEDULE OF SUPPLEMENTAL CASH F

SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating lease right-of-use assets	$ 817	$ 1,243
Current Operating lease liabilities	596	544
Non-current operating lease liabilities	338	799
Operating cash flows from operating leases (cash paid in thousands)	$ 547	$ 743
Weighted Average Remaining Lease Term (years)	1 year 7 months 2 days	2 years 5 months 5 days
Weighted Average Discount Rate of operating leases	5.40%	5.45%

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) - Intec Pharma Ltd. [Member] $ in Thousands	Dec. 31, 2020USD ($)
2021	$ 625
2022	329
2023	22
Total lease payments	976
Less imputed interest	(42)
Total	$ 934

SCHEDULE OF IMPAIRMENT ASSESSME

SCHEDULE OF IMPAIRMENT ASSESSMENT (Details) - Subsidiaries [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Production Line [Member]
Cost/Liability	$ 9,568
Impairment charge	(9,568)
Fair value
Equipment [Member]
Cost/Liability	7,812
Impairment charge	(4,095)
Fair value	3,717
Liability for LTS's facility upgrading costs [Member]
Cost/Liability	(2,244)
Impairment charge
Fair value	(2,244)
AP-CD/LD Assets, net [Member]
Cost/Liability	15,136
Impairment charge	(13,663)
Fair value	$ 1,473

COMMITMENTS AND CONTINGENT LI_3

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) - Intec Pharma Ltd. [Member] ₪ in Thousands, $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2020ILS (₪)	Dec. 31, 2020EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2018EUR (€)	Jul. 13, 2005
Other income				$ 1,500
Joint Venture and Exclusive License Agreement [Member]
Royalties rate paid based on the overall net income from the sale of the products							3.00%
Royalties rate paid based on sub-licenses on any payment or benefit whatsoever that may receive from sub-licenses							15.00%
Cooperation Agreements - Termination Fee from Novartis [Member]
Other income				1,500
Grants from the IIA [Member]
Total amount of grants received from the IIA	$ 11,300
Grants from the IIA [Member] | Israel, New Shekels
Total amount of grants received from the IIA | ₪		₪ 42,300
Grants from the IIA [Member] | Minimum [Member]
Royalties rate	3.00%
Grants from the IIA [Member] | Maximum [Member]
Royalties rate	5.00%
Lease Agreements [Member]
Bank guarantee	$ 157			147
LTS Process Development Agreement [Member]
Total cost of the equipment					$ 7,800
Impairment charge				4,100
Fair value of equipment				3,700
Additional amount recognized as liability in respect to facility upgrading costs	2,450
LTS Process Development Agreement [Member] | Euro Member Countries, Euro
Total cost of the equipment | €						€ 6.8
Additional amount recognized as liability in respect to facility upgrading costs | €			€ 2
Impairment Assessment [Member]
Impairment charge of AP-CD/LD Assets, net				$ 13,700
Net book value of equipment	3,700
Lawsuit [Member]
Plaintiffs pecuniary damages	750
Settlement amount to each plaintiff	$ 125
Lawsuit [Member] | Israel, New Shekels
Plaintiffs pecuniary damages | ₪		2,400
Settlement amount to each plaintiff | ₪		₪ 400

SCHEDULE OF OPTIONS GRANTED TO

SCHEDULE OF OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS (Details) - Share Options [Member] - Intec Pharma Ltd. [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employees [Member]
Number of options granted	85,000	73,250
Exercise price range, minimum	$ 6.15	$ 8.94
Exercise price range, maximum	$ 8.57	$ 152.8
Vesting period		3 years
Expiration	7 years	7 years
Employees [Member] | Minimum [Member]
Vesting period	1 year 3 months 15 days
Employees [Member] | Maximum [Member]
Vesting period	3 years
Directors [Member]
Number of options granted	10,000	7,000
Exercise price range, minimum		$ 12.4
Exercise price range, maximum	$ 6.15	$ 97.2
Vesting period	3 years	3 years
Expiration	7 years	7 years

SCHEDULE OF WEIGHTED AVERAGE FA

SCHEDULE OF WEIGHTED AVERAGE FAIR VALUE OF OPTIONS GRANTED (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Intec Pharma Ltd. [Member]
Weighted average fair value	$ 4.38	$ 55.28

SCHEDULE OF UNDERLYING DATA USE

SCHEDULE OF UNDERLYING DATA USED FOR COMPUTING THE FAIR VALUE OF OPTIONS (Details) - Intec Pharma Ltd. [Member] - Underlying Data Used for Computing the Fair Value of Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Dividend yield	0.00%	0.00%
Expected term	5 years	5 years
Minimum [Member]
Value of ordinary share	$ 5.60	$ 10.2
Expected volatility	102.58%	53.32%
Risk-free interest rate	0.28%	1.65%
Maximum [Member]
Value of ordinary share	$ 6.20	$ 149.2
Expected volatility	110.40%	100.04%
Risk-free interest rate	1.42%	2.57%

SCHEDULE OF NUMBER OF OPTIONS O

SCHEDULE OF NUMBER OF OPTIONS OUTSTANDING (Details) - Intec Pharma Ltd. [Member] - $ / shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Employees and Directors [Member] | 2005 Plan [Member]
Number of Options, Outstanding at beginning of period		4,134	14,773
Outstanding at beginning of period, per share	[1]	$ 812	$ 550.4
Number of Options, Exercised			(1)
Exercised, per share	[1]		$ 10
Number of Options, Forfeited			(4,295)
Forfeited, per share			$ 465
Number of Options, Expired		(4,134)	(6,343)
Expired, per share	[1]	$ 812	$ 437.8
Number of Options, Outstanding at end of period			4,134
Outstanding at end of period, per share	[1]		$ 812
Number of Options, Expired		4,134	6,343
Employees and Directors [Member] | 2015 Plan [Member]
Number of Options, Outstanding at beginning of period		196,145	156,909
Outstanding at beginning of period, per share	[2]	$ 82.6	$ 117
Number of Options, Exercised			(4,982)
Exercised, per share	[2]		$ 56.6
Number of Options, Forfeited		(18,249)	(22,537)
Forfeited, per share	[2]	$ 39.47	$ 80
Number of Options, Expired		(9,816)	(13,495)
Expired, per share	[2]	$ 41.18	$ 140
Number of Options, Outstanding at end of period		263,080	196,145
Outstanding at end of period, per share	[2]	$ 59.87	$ 82.6
Number of Options, Expired		9,816	13,495
Number of Options, Granted		95,000	80,250
Granted, per share	[2]	$ 7.09	$ 69
Consultants [Member] | 2005 Plan [Member]
Number of Options, Outstanding at beginning of period			402
Outstanding at beginning of period, per share	[1]		$ 10
Number of Options, Exercised			(127)
Exercised, per share	[1]		$ 10
Number of Options, Forfeited
Forfeited, per share
Number of Options, Expired			(275)
Expired, per share	[1]		$ 10
Number of Options, Outstanding at end of period
Outstanding at end of period, per share	[1]
Number of Options, Expired			275
[1]	Weighted average price in NIS per share.
[2]	Weighted average price in USD per share.

SCHEDULE OF INFORMATION CONCERN

SCHEDULE OF INFORMATION CONCERNING OUTSTANDING AND EXERCISABLE OPTIONS (Details) - Intec Pharma Ltd. [Member]	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Options outstanding, Number of options outstanding at the end of year	263,080
Options exercisable, Number of options exercisable at the end of year	141,327
Exercise Price Per Share One [Member]
Exercise price per share, minimum | $ / shares	$ 6.15
Exercise price per share, maximum | $ / shares	$ 6.67
Options outstanding, Number of options outstanding at the end of year	60,750
Options outstanding, Weighted average remaining contractual life	6 years 7 months 21 days
Options exercisable, Number of options exercisable at the end of year
Options exercisable, Weighted average remaining contractual life	0 years
Exercise Price Per Share Range Two [Member]
Exercise price per share, minimum | $ / shares	$ 8.58
Exercise price per share, maximum | $ / shares	$ 8.94
Options outstanding, Number of options outstanding at the end of year	60,416
Options outstanding, Weighted average remaining contractual life	4 years 11 months 4 days
Options exercisable, Number of options exercisable at the end of year	28,810
Options exercisable, Weighted average remaining contractual life	3 years 10 months 28 days
Exercise Price Per Share Range Three [Member]
Exercise price per share, minimum | $ / shares	$ 11.1
Exercise price per share, maximum | $ / shares	$ 18
Options outstanding, Number of options outstanding at the end of year	21,000
Options outstanding, Weighted average remaining contractual life	5 years 8 months 16 days
Options exercisable, Number of options exercisable at the end of year	8,668
Options exercisable, Weighted average remaining contractual life	5 years 8 months 16 days
Exercise Price Per Share Range Four [Member]
Options outstanding, Number of options outstanding at the end of year	11,224
Options outstanding, Weighted average remaining contractual life	5 years 4 months 13 days
Options exercisable, Number of options exercisable at the end of year	11,224
Options exercisable, Weighted average remaining contractual life	5 years 4 months 13 days
Options outstanding, Exercise price per share | $ / shares	$ 70.52
Exercise Price Per Share Range Five [Member]
Exercise price per share, minimum | $ / shares	82.8
Exercise price per share, maximum | $ / shares	$ 89.3
Options outstanding, Number of options outstanding at the end of year	20,440
Options outstanding, Weighted average remaining contractual life	5 years 18 days
Options exercisable, Number of options exercisable at the end of year	14,692
Options exercisable, Weighted average remaining contractual life	4 years 11 months 12 days
Exercise Price Per Share Six [Member]
Options outstanding, Number of options outstanding at the end of year	4,000
Options outstanding, Weighted average remaining contractual life	5 years 5 months 27 days
Options exercisable, Number of options exercisable at the end of year	1,996
Options exercisable, Weighted average remaining contractual life	5 years 5 months 27 days
Options outstanding, Exercise price per share | $ / shares	$ 97.2
Exercise Price Per Share Range Seven [Member]
Exercise price per share, minimum | $ / shares	103.8
Exercise price per share, maximum | $ / shares	$ 109.2
Options outstanding, Number of options outstanding at the end of year	21,750
Options outstanding, Weighted average remaining contractual life	4 years 10 months 6 days
Options exercisable, Number of options exercisable at the end of year	21,188
Options exercisable, Weighted average remaining contractual life	4 years 10 months 14 days
Exercise Price Per Share Range Eight [Member]
Exercise price per share, minimum | $ / shares	$ 120
Exercise price per share, maximum | $ / shares	$ 122
Options outstanding, Number of options outstanding at the end of year	11,542
Options outstanding, Weighted average remaining contractual life	7 months 6 days
Options exercisable, Number of options exercisable at the end of year	11,542
Options exercisable, Weighted average remaining contractual life	7 months 6 days
Exercise Price Per Share Nine [Member]
Options outstanding, Number of options outstanding at the end of year	19,000
Options outstanding, Weighted average remaining contractual life	6 years 11 months 12 days
Options exercisable, Number of options exercisable at the end of year	19,000
Options exercisable, Weighted average remaining contractual life	6 years 11 months 12 days
Options outstanding, Exercise price per share | $ / shares	$ 134
Exercise Price Per Share Range Ten [Member]
Exercise price per share, minimum | $ / shares	152.6
Exercise price per share, maximum | $ / shares	$ 152.8
Options outstanding, Number of options outstanding at the end of year	22,958
Options outstanding, Weighted average remaining contractual life	4 years 5 months 1 day
Options exercisable, Number of options exercisable at the end of year	14,207
Options exercisable, Weighted average remaining contractual life	3 years 11 months 23 days
Exercise Price Per Share Eleven [Member]
Options outstanding, Number of options outstanding at the end of year	10,000
Options outstanding, Weighted average remaining contractual life	6 years 10 months 28 days
Options exercisable, Number of options exercisable at the end of year	10,000
Options exercisable, Weighted average remaining contractual life	6 years 10 months 28 days
Options outstanding, Exercise price per share | $ / shares	$ 171.2

SCHEDULE OF EFFECT OF SHARE-BAS

SCHEDULE OF EFFECT OF SHARE-BASED COMPENSATION (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based compensation	$ 1,148	$ 3,221
Research and Development Expense [Member]
Share-based compensation	289	1,634
General and Administrative Expense [Member]
Share-based compensation	$ 859	$ 1,587

SHARE CAPITAL (Details Narrativ

SHARE CAPITAL (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Aug. 10, 2020	May 06, 2020	Feb. 03, 2020	Feb. 28, 2021	Feb. 28, 2021	Jul. 31, 2020	Jan. 31, 2020	Dec. 31, 2019	Dec. 02, 2019	Aug. 22, 2019	Jul. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Jul. 15, 2020	Jun. 30, 2018	Dec. 31, 2017	Jul. 31, 2016	Jan. 31, 2016
Intec Pharma Ltd. [Member]
Proceeds from issuance of ordinary shares, net of issuance costs												$ 421	$ 2,086
Proceeds from issuance of ordinary shares and warrants, net of issuance costs (in Dollars)												5,692
Proceeds from exercise of warrants (in Dollars)												769
Proceeds from issuance of ordinary shares and warrants, net of issuance costs												4,426
Proceeds from issuance of ordinary shares and pre-funded warrants, net of issuance costs												4,599
Proceeds from exercise of pre-funded warrants												$ 71
Intec Pharma Ltd. [Member] | Plan 2015 [Member]
Number of ordinary shares reserved for issuance under the 2015 plan						175,000		50,000			175,000		50,000		50,000	105,000	35,000	35,000
Number of shares available for grant												181,027
Maximum term of award												10 years
Intec Pharma Ltd. [Member] | Increase In Authorized Share Capital [Member]
Authorized ordinary shares before the increase in authorized share capital														5,000,000
Authorized ordinary shares post the increase in authorized share capital														17,500,000
Intec Pharma Ltd. [Member] | Exercise of Warrants [Member] | Subsequent Event [Member]
Proceeds from exercise of warrants (in Dollars)					$ 956
Intec Pharma Ltd. [Member] | Repricing of Options Previously Granted [Member]
Number of options previously granted										63,183
Exercise price (in Dollars per share)										$ 8.94
Total incremental fair value of options previously granted										$ 253
Risk-free interest rate										1.50%
Dividend yield										0.00%
Intec Pharma Ltd. [Member] | Repricing of Options Previously Granted [Member] | Minimum [Member]
Expected volatility										99.00%
Expected term										2 years 7 months 6 days
Intec Pharma Ltd. [Member] | Repricing of Options Previously Granted [Member] | Maximum [Member]
Expected volatility										122.00%
Expected term										4 years 4 months 24 days
Intec Pharma Ltd. [Member] | Underwritten Public Offering [Member]
Number of shares issued			764,000
Issuance expenses			$ 800
Number of pre-funded warrants issued			48,500
Number of warrants issued			812,500
Pre-funded warrants exercise price (in Dollars per share)			$ 0.002
Combined price of share and warrant (in Dollars per share)			8
Exercise price per share			$ 8
Proceeds from issuance of ordinary shares and warrants, net of issuance costs (in Dollars)			$ 5,700
Outstanding warrants												767,875
Intec Pharma Ltd. [Member] | Underwritten Public Offering [Member] | Exercise of Warrants [Member]
Number of warrants exercised											44,625
Proceeds from exercise of warrants (in Dollars)											$ 357
Intec Pharma Ltd. [Member] | Underwritten Public Offering [Member] | Exercise of Warrants [Member] | Subsequent Event [Member]
Number of warrants exercised				20,000
Proceeds from exercise of warrants (in Dollars)				$ 160
Intec Pharma Ltd. [Member] | Registered Direct Offering and Concurrent Private Placement [Member]
Number of shares issued		814,598
Issuance expenses		$ 500
Number of warrants issued		407,299
Exercise price per share		$ 4.90
Outstanding warrants												323,226
Purchase price per share		$ 6.138
Term of the warrants		five and one-half years
Proceeds from issuance of ordinary shares and warrants, net of issuance costs		$ 4,500
Intec Pharma Ltd. [Member] | Registered Direct Offering and Concurrent Private Placement [Member] | Exercise of Warrants [Member]
Number of warrants exercised						84,073
Proceeds from exercise of warrants (in Dollars)						$ 412
Intec Pharma Ltd. [Member] | Registered Direct Offering and Concurrent Private Placement [Member] | Exercise of Warrants [Member] | Subsequent Event [Member]
Number of warrants exercised				162,500
Proceeds from exercise of warrants (in Dollars)				$ 796
Intec Pharma Ltd. [Member] | Registered Direct Offering [Member] | Aspire Capital Fund L L C [Member]
Number of shares issued	356,250
Issuance expenses	$ 330
Number of pre-funded warrants issued	356,250
Exercise price per share	$ 0.20
Purchase price per share	7.022
Purchase price of pre-funded warrants per share	$ 6.822
Proceeds from issuance of ordinary shares and pre-funded warrants, net of issuance costs	$ 4,600
Proceeds from exercise of pre-funded warrants												$ 71
Proceeds from issuance of ordinary shares and pre-funded warrants including the exercise of pre-funded warrants, net of issuance costs												$ 4,700
Subsidiaries [Member] | Repricing of Options Previously Granted [Member]
The incremental fair value of fully vested options previously granted										$ 62
Sales Agreement [Member] | Cowen [Member]
Number of shares issued							41,569	97,226
Average price per share							$ 10.50	$ 22.6					$ 22.6
Proceeds from issuance of ordinary shares, net of issuance costs							$ 421	$ 2,100
Issuance expenses							$ 15	$ 112
Purchase Agreement With Aspire [Member] | Intec Pharma Ltd. [Member]
Aspire's commitment to purchase aggregate amount of the Company's ordinary shares under the purchase agreement (in Dollars)									$ 10,000
Number of shares issued to Aspire									30,626

SCHEDULE OF SUPPLEMENTARY FINAN

SCHEDULE OF SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
a. Prepaid expenses and other receivable:
Institutions	$ 25	$ 1,836
Termination fee, Novartis (see note 6b(1))		1,500
Prepaid expenses	212	194
Advances to suppliers		3
Interest receivable		3
Other receivables	60	147
Prepaid expenses and other receivable	297	3,683
b. Accounts payable and accruals - other:
Expenses payable	2,859	2,838
Salary and related expenses, including social security and other taxes	1,057	1,277
Current operating lease liabilities (see note 6d)	596	544
Accrual for vacation days and recreation pay for employees	180	154
Other	274	22
Accounts payable and accruals - other	4,966	4,835
Financial income:
Interest on cash and cash equivalents	39	330
Gains from changes in fair value of marketable securities	2	13
Financial income	41	343
Financial expenses -
Loss from changes in exchange rates	(206)	(180)
Bank fees	(10)	(15)
Financial expenses	(216)	(195)
Financial income (expenses), net	$ (175)	$ 148

SCHEDULE OF DEFERRED INCOME TAX

SCHEDULE OF DEFERRED INCOME TAXES (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net operating loss carry forward	$ 39,924	$ 33,316
Research and Development expenses	2,910	6,209
Impairment of long-lived assets	3,143	3,143
Issuance costs	274	216
Other	1,246	1,138
Less—valuation allowance	(47,497)	(44,022)	$ (32,684)
Net deferred tax assets

SCHEDULE OF CHANGE IN VALUATION

SCHEDULE OF CHANGE IN VALUATION ALLOWANCE (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance at the beginning of the year	$ 44,022	$ 32,684
Changes during the year	3,475	11,338
Balance at the end of the year	$ 47,497	$ 44,022

SCHEDULE OF COMPONENTS OF LOSS

SCHEDULE OF COMPONENTS OF LOSS BEFORE INCOME TAX (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Intec	$ (14,180)	$ (47,331)
Subsidiary	176	370
Income (loss) before income tax	$ (14,004)	$ (46,961)

SCHEDULE OF UNRECOGNIZED TAX BE

SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance at the beginning of the year	$ 604	$ 309
Increase in uncertain tax positions for the current year	87	295
Balance at the end of the year	$ 691	$ 604

TAXES ON INCOME (Details Narrat

TAXES ON INCOME (Details Narrative) - Intec Pharma Ltd. [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net carry forward tax losses	$ 173,600
Tax expenses	124	$ 638
Subsidiary [Member]
Tax expenses recorded following full valuation allowance with respect to the subsidiary's share-based compensation expenses	$ 87	$ 562
ISRAEL
Federal statutory tax	23.00%
UNITED STATES
Federal statutory tax	21.00%	21.00%
Relevant state tax rate	7.00%	7.00%
UNITED STATES | Maximum [Member]
Federal statutory tax			35.00%
UNITED STATES | Minimum [Member]
Federal statutory tax			21.00%

EVENTS SUBSEQUENT TO DECEMBER_2

EVENTS SUBSEQUENT TO DECEMBER 31, 2020 (Details Narrative) - Intec Pharma Ltd. [Member] - USD ($)	Mar. 15, 2021	Apr. 30, 2021	Mar. 31, 2021	Feb. 28, 2021	Dec. 31, 2020	Dec. 31, 2019
Proceeds from exercise of warrants					$ 769,000
Proceeds from issuance of ordinary shares					$ 421,000	$ 2,086,000
Subsequent Event [Member] | Unaudited [Member]
The company's financial transfers to Decoy for transaction expenses			$ 650,000
Company's financial transfers to Decoy for transaction expenses that was recorded as general and administrative expenses			$ 350,000
Subsequent Event [Member] | Merger Agreement [Member]
Percentage of share exchange ratio in the mergers for the securityholders	75.00%
Amount of basis share exchange ratios calculation	$ 30,000,000
Percentage Of Share Exchange Ratio In The Merger For The Security holders	25.00%
AmountOfBasisShareExchangeRatioCalculations	$ 10,000,000
The minimum combined net cash of Intec Parent	30,000,000
The maximum combined net cash of Intec Parent	50,000,000
The break-up fee that the Company or Decoy may be require to pay in connection with the termination of the Merger, under specified circumstances	1,000,000
The Company's deposit in favor of Decoy that may be forfeit in connection with the termination of the Merger, under specified circumstances	$ 350,000
Subsequent Event [Member] | Purchase Agreement [Member] | Unaudited [Member] | Aspire Capital Fund L L C [Member]
Number of ordinary shares sold		319,393
Proceeds from issuance of ordinary shares		$ 1,200,000
Exercise of Warrants [Member] | Subsequent Event [Member]
Number of warrants issued				182,500
Proceeds from exercise of warrants				$ 956,000